Cronos Group Inc.

TSX:CRON.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.57 -0.27%

-$0.01 today

Market cap
$1.67B
Beta
1.25
P/E (TTM)
-488.1
EPS (TTM)
-$0.01
52W Low $2.54High $4.66

Volume 0.15M

Average 0.19M

CRON.TO Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Cronos Group Inc.TSX: CRON.TO

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q1 FY2026 accounts receivables was $3.9M, compared with -$2.34M a year earlier. Trailing-twelve-month accounts receivables was -$19.83M. Over 3 fiscal years it compounded at +113.0% a year.

Context

  • Accounts receivables amounted to 17.6% of revenue in FY2025, up 15.4 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $3.9M or moves back toward the trailing-twelve-month quarterly average of -$4.96M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.9M+121.0% QoQ
Last fiscal yearDec 2025
-$26.2M+942.3% YoY
LTMMar 2026
-$19.83M+490.3% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+266.9%——
1 year+942.3%——
3-year CAGR+113.0%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(26.2M) USD
Year-over-year change
-942.3%

Accounts Receivables vs competitors

How CRON.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +490.3% is the highest of 6, against a peer median of +25.5%.
  • Accounts receivables amounts to 12.4% of revenue for CRON.TO, versus a peer median of 1.1%.
CRON.TO Competitors
Accounts Receivables for CRON.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WELL.TOWELL Health Technologies Corp.LTM Mar 2026CA$39.31M CAD+177.5%—2.7%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$30.28M CAD+25.5%+0.1%5.9%
CRON.TOCronos Group Inc.LTM Mar 2026$19.83M USD+490.3%+113.0%12.4%
TLRY.TOTilray Brands, Inc.LTM Feb 2026$9.62M USD-18.4%+45.0%1.1%
EXE.TOExtendicare Inc.LTM Jun 2026CA$1.78M CAD-80.3%+66.2%0.1%
SIA.TOSienna Senior Living Inc.LTM Sep 2026CA$141K CAD+113.3%—0.0%
Peer median (excluding CRON.TO) —+25.5%+45.0%1.1%

Competitors are the stored peer set for CRON.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(397.2M)(168.73M)(74.55M)40.02M(9.61M)
Depreciation & Amortization15.4M13.12M8.11M9.34M14.48M
Deferred Income Tax222.22M043.32M00
Stock-Based Compensation10.15M15.12M8.77M8.7M0
Change in Working Capital(2.01M)20.66M(26.47M)(311K)(35.02M)
Accounts Receivables(13.16M)(2.71M)9.21M(2.51M)(26.2M)
Inventory11.57M(7.22M)7.4M7.42M(10.58M)
Accounts Payables(2.37M)(863K)(773K)(7.45M)1.13M
Other Working Capital1.97M31.45M(42.3M)2.24M636.96K
Other Non-Cash Items(2.18M)30.89M(2.01M)(38.9M)56.47M
Operating Cash Flow(153.62M)(88.95M)(42.84M)18.84M26.32M
Capital Expenditures(12.26M)(5.03M)(3.42M)(13.15M)(26.17M)
Acquisitions (Net)(1.12M)0724K5.99M2.9M
Purchases of Investments(230M)(271.38M)(608.25M)0(59.44M)
Sales of Investments215.3M268.87M532.84M185.82M5.15M
Other Investing Activities(819K)5.7M18.61M(4.25M)0
Investing Cash Flow(28.9M)(1.84M)(59.5M)175.15M(77.9M)
Debt Repayment00000
Common Stock Issued15.73K0000
Common Stock Repurchased0(2.85M)(1.03M)0(9.91M)
Dividends Paid00000
Other Financing Activities(13.46M)(42.36K)(2.47K)(1.23M)(10.34M)
Financing Cash Flow(13.44M)(2.9M)(1.03M)(1.23M)(20.25M)
Effect of Forex Changes4.91M(28.64M)8.01M(3.25M)(37.24M)
Net Change in Cash(191.05M)(122.33M)(95.35M)189.51M(109.07M)
Free Cash Flow(165.88M)(93.98M)(46.26M)5.69M151.61K

Cronos Group Inc.

TSX:CRON.TO

Intrinsic Alpha fair value

Locked

Current Price

$4.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.